In the context of celiac disease, TGM2 pathologically modifies the lining of the small intestine and triggers an autoimmune response against TGM2 and the tissue itself, leading to bowel inflammation, truncated villi, and scalloping [26]; ulcers and bowel obstructions [27]; as well as increased risks of adenocarcinoma of the small intestine and enteropathy-associated T-cell lymphoma. This evidence concerns the gene TGM2 and small intestine adenocarcinoma.